Different effectiveness of cyproterone acetate doses in treatment of acne

V. Leo,G. Morgante

DOI: https://doi.org/10.1046/j.1365-2265.2003.16911.x

2003-02-01

Clinical Endocrinology

Abstract:Sirs , We read with interest the recent study by Carmina and Lobo (2002). In a randomized controlled study, the authors demonstrated that low and high doses of cyproterone acetate (CPA) with ethinyl oestradiol (EE) were equally effective for treating hyperandrogenic women with moderate to severe acne, and had similar effects to low-dose flutamide. They postulated that most antiandrogens, including flutamide, are effective in treating hyperandrogenic acne and that low doses may be sufficient. They showed that low and high doses of CPA had the same efficacy. The use of low doses of flutamide had similar results to CPA. They also found that finasteride was less effective than other antiandrogenic drugs in treating hyperandrogenic acne. In recent years several studies on hyperandrogenism and related acne have demonstrated the efficacy of CPA treatment. van Wayjen and van den Ende (1995) investigated the effects and side-effects of long-term treatment with CPA. Hammerstein’s reverse sequential regimen (10 days 100 mg CPA, 21 days 50 g EE) was used in most cases, although postmenopausal and hysterectomized women received 50 mg CPA/day continuously as monotherapy. The results of the treatment were good or very good in more than 90% of acne patients. Side-effects were recorded in 23% of cases; most were mild and transient, and only necessitated discontinuation of therapy in 9% of patients. Blood and biochemical parameters were within the normal ranges. High-dose CPA with or without EE was found to be an effective and safe, long-term treatment of acne in women. Falsetti et al . (2001) examined the effect of long-term treatment (60 cycles) with the EE/CPA pill, and follow-up after 6 months in women with polycystic ovarian syndrome (PCOS) and moderate or severe acne. The endocrine profile was significantly modified after only six cycles ( P < 0·001). Acne disappeared in all patients within 12–24 cycles. However, 6 months after the end of therapy, endocrine parameters were identical to the starting ones and acne reappeared. Falsetti et al . (2001) found that acne rapidly returns to pretreatment levels after low-dose CPA therapy. Our experience with low-dose CPA for treating acne has not shown the good results of Carmina and Lobo, especially for moderate to severe acne. In particular, when the treatment with low-dose CPA was stopped, we observed a return of acne, often initially worse than before therapy. When treatment was based on doses of 25 or 50 mg CPA in Hammenstein’s reverse sequential regimen, acne cleared up in all subjects after 9–12 months of treatment. Follow-up showed an absence of acne and very few women required a second 12-month cycle of treatment (unpublished data). In our gynaecological endocrine centre we see many women with moderate to severe acne previously treated with long courses of Diane (2, CPA plus 35 μ g EE) by dermatologists and general practitioners. The women report an improvement during treatment but a relapse of acne afterwards. Many have other endocrine abnormalities, especially PCOS and high serum levels of androgens. Side-effects of treatment with Diane include weight gain, swollen breasts and increased blood pressure in many women. Most studies investigating low-dose CPA treatment in hyperandrogenic patients with acne suggest that clearing of acne is not necessarily accompanied by an improvement in the other endocrine abnormalities of hyperandrogenic patients. Not all studies that have assessed the effects of Diane on acne have a follow-up that confirms the efficacy after the end of treatment (Fugere et al ., 1990; Gollnick et al ., 1999). Readers of the paper by Carmina and Lobo (2002) might be led to understand that low-dose cyproterone acetate treatment (Diane) is associated with a persistent and total reduction of acne, but this is incorrect. The paper by Carmina and Lobo does not focus on the follow-up of hyperandrogenic women with moderate to severe acne or on the relationship between dose of cyproterone acetate and speed of resolution of acne. V. De Leo and G. Morgante Department of Obstetrics and Gynecology, University of Siena, Italy